Indian IT stocks and AI: These are the bull and bear cases
Source: Investing.com

India’s four leading IT stocks are up 1.3%–3.9% in the cited Oct. 13 session, despite year-to-date declines and pressure from AI-driven pricing deflation. Revenue trends remain weak: TCS revenue fell from $29.89B to $28.60B in FY2026, Infosys grew 4.6%, and Infosys cut FY27 growth guidance to 1.5%–3.0%. AI is showing early revenue traction at TCS ($3.1B annualized, up nearly 20% quarter over quarter) and HCLTech, but investors face the risk that AI gains merely offset shrinking legacy business.
Analysis
The key distinction is not who can sell AI work, but who can convert it into net growth after price compression in legacy services. AI project revenue and deal wins are weak evidence if they displace billable implementation work or arrive at lower unit economics; watch constant-currency organic growth, net headcount additions, pricing, and conversion of bookings into revenue. That makes the reported AI ramp at Tata Consultancy Services and HCLTech promising but not yet proof of an earnings inflection. HCLTech’s data-center exposure is a longer-dated option, not a near-term earnings underpinning; execution, utilization, and customer commitments remain unverified.
Near term (days), the session’s gains are not confirmation of a durable turn. Over the next 1–3 months, guidance revisions and quarterly commentary on discretionary client spending, renewals, and AI cannibalization should drive dispersion. Over 6–18 months, firms that automate delivery while retaining customer ownership may protect margins; those paid mainly for routine labor face volume growth that may not offset lower pricing. Currency conversion also clouds comparisons of USD revenue, so use constant-currency growth before inferring operating deterioration.
Contrarian angle: the market may over-credit AI revenue headlines and underweight the possibility that cheaper delivery expands total project demand. Conversely, low headline P/Es and third-party fair-value estimates do not establish a floor if earnings estimates are still resetting. The thesis is falsified if subsequent results show sustained constant-currency growth and stable pricing across the weaker names, or if AI-led bookings fail to convert while core growth and margins deteriorate further.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment
Key Decisions for Investors
- Avoid a broad India IT long on a one-session bounce. Treat the sector as a dispersion trade; do not use the article’s fair-value estimates as a valuation anchor.
- Consider a small relative-value short in WIT versus a long in HCLTech, conditional on confirming comparable forward growth, valuation, and borrow costs. The thesis is weaker evidence of offsetting AI growth at Wipro versus HCLTech’s early services contribution; cap risk because HCLTech’s premium may already price in execution.
- Keep INFY underweight versus stronger evidence of AI-to-core revenue conversion until guidance stabilizes. Reassess after the next results using constant-currency growth, pricing, large-deal conversion, and operating margin; a sustained improvement in those measures would invalidate the underweight.
- Use upcoming earnings as the 1–3 month catalyst, not near-dated options absent a clear event-volatility edge. Reduce or exit relative positions if weaker names deliver two consecutive quarters of improving constant-currency growth without margin deterioration, or if the relative valuation spread becomes excessive.
More News
- Why is LVMH Moet Hennessy Louis Vuitton stock sliding today?
- HSBC downgrades Adobe stock rating on open-source competition
- Satya Nadella went from an H-1B worker to Microsoft CEO. The Trump administration just shut that path for his employees
- HSBC Moves to Wall Street Bonus Model
- Mubadala, Kotak, HSBC on Repricing Risk
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs